Patents Represented by Attorney, Agent or Law Firm William S. Feiler
  • Patent number: 6541483
    Abstract: The present invention relates to several novel acridone-derived compounds of of formula (I) or (II). These compounds are potent anti-viral agents, useful in the treatment of viral diseases, such as Human Immunodeficiency Virus. In addition, these compounds are anti-neoplastic agents useful in the treatment of various forms of cancer. wherein R1 and R2 are independently —H, —OH, amino, alkylamino, dialkylamino, alkoxy, alkyl, haloalkyl or halogen; n is 2 to 6, X and X′ are independently —N or —NO2; Y and Y′ are independently —N or —CH, or —H; and the double-slash represents a double bond or no bond.
    Type: Grant
    Filed: January 15, 2001
    Date of Patent: April 1, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Christopher J. Michejda, Marek W. Cholody, William G. Rice, James A. Turpin
  • Patent number: 6475741
    Abstract: An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: November 5, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kouji Matsushima, Teizo Yoshimura, Edward J. Leonard, Joost Oppenheim, Ettore Appella, Stephen D. Showalter
  • Patent number: 6451763
    Abstract: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule. In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: September 17, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Joyce Tombran-Tink, Gerald J. Chader, Sofia Patricia Becerra, Ignacio R. Rodriguez, Fintan R. Steele, Lincoln V. Johnson
  • Patent number: 6417338
    Abstract: The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.
    Type: Grant
    Filed: January 17, 2000
    Date of Patent: July 9, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Mary Stracke, Lance Liotta, Elliott Schiffman, Henry Krutzch, Jun Murata
  • Patent number: 6413544
    Abstract: Highly efficient cationic liposomes have been developed as an improved delivery system for biologically active reagents. A novel structure, the sandwich liposome, is formed and comprises one or more biologically active agents sandwiched (and thus sequestered) between the lipid bilayers. This structure protects the incoming agent and accounts for the high efficiency of in vivo delivery and for the broad tissue distribution of the sandwich liposome complexes. These novel liposomes are also highly efficient carriers of nucleic acids. By using extruded DOTAP:cholesterol liposomes to form complexes with DNA encoding specific proteins, expression has been improved dramatically. Highest expression was achieved in the lung, while increased expression was detected in several organs and tissues.
    Type: Grant
    Filed: October 4, 1999
    Date of Patent: July 2, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nancy Smyth-Templeton, George N. Pavlakis
  • Patent number: 6376659
    Abstract: An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity of NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: April 23, 2002
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Kouji Matsushima, Teizo Yoshimura, Edward J. Leonard, Joost Oppenheim, Ettore Appella, Stephen D. Showalter
  • Patent number: 6322981
    Abstract: The present invention relates to the simultaneous and specific identification of the variant forms of &agr;-thalassemia. This invention utilizes simple and readily available equipment to rapidly identify, diagnose and differentiate the different forms of &agr;-thalassemia. Specifically, the present invention relates to a simple and rapid non-radioisotopic technique for the diagnosis and differentiation of the common forms of &agr;-thalassemia has been developed. This approach works on any biological tissue including blood, wherein the assay works equally well with fresh blood and dried blood samples stored on filter paper.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: November 27, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Griffin P. Rodgers, Delia C. Tang
  • Patent number: 6319687
    Abstract: Nucleic acids encoding the neurotrophic protein known as pigment epithelium-derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: November 20, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gerald J. Chader, S. Patricia Becerra, Joyce Tombran-Tink, Lincoln V. Johnson, Fintan R. Steele, Ignacio Rodriguez
  • Patent number: 6270778
    Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: August 7, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Yutaka Kawakami, Steven A. Rosenberg
  • Patent number: 6197499
    Abstract: The present invention relates to a method of detecting a DNA sequence by means of a DNA:DNA hybrid in real time using fluorescence. The present invention eliminates the need to use radioactive probes to detect the DNA and eliminates the delay needed for autoradiographic exposure of the X-ray to the radioactive label.
    Type: Grant
    Filed: July 27, 1992
    Date of Patent: March 6, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stephen H. Hughes, Ramesh Kumar, John Brumbaugh
  • Patent number: 6187775
    Abstract: The present invention relates to several novel acridone-derived compounds of of formula (I) or (II). These compounds are potent anti-viral agents, useful in the treatment of viral diseases, such as Human Immunodeficiency Virus. In addition, these compounds are anti-neoplastic agents useful in the treatment of various forms of cancer. wherein R1 and R2 are independently —H, —OH, amino, alkylamino, dialkylamino, alkoxy, alkyl, haloalkyl or halogen; n is 2 to 6, X and X′ are independently —N or —NO2; Y and Y′ are independently —N or —CH, or —H; and the double-slash represents a double bond or no bond.
    Type: Grant
    Filed: September 22, 1998
    Date of Patent: February 13, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Christopher J. Michejda, Marek W. Cholody, William G. Rice, James A. Turpin
  • Patent number: 5565437
    Abstract: Methods of treating a human infected with human immunodeficiency virus (HIV), such as a human with AIDS, with the purina nucleotides 2',3'-dideoxy-2'-beta-fluoroadenosine (FddA) and 2',3'-dideoxy-2'-beta-fluoroinosine (FddI) are disclosed. These nucleotides are stable in an acid environment and thus can be used for oral administration. Methods of inhibiting human immunodeficiency virus replication in a human T cell using these purina nucleotides are also disclosed.
    Type: Grant
    Filed: November 10, 1992
    Date of Patent: October 15, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Victor E. Marquez, John S. Driscoll, Christopher K-H. Tseng, James A. Kelley, David G. Johns, Hiroaki Mitsuya
  • Patent number: 5495010
    Abstract: Purine nucleosides active against human immunodeficiency virus which are substituted at the 2'-position by a strong electronegative group such as fluorine are stable in an acid environment and thus can be used for oral administration.
    Type: Grant
    Filed: September 19, 1991
    Date of Patent: February 27, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Victor E. Marquez, John S. Driscoll, Christopher K-H. Tseng, James A. Kelley, David G. Johns, Hiroaki Mitsuya
  • Patent number: 5272065
    Abstract: Gene expression in a cell can be regulated or inhibited by incorporating into or associating with the genetic material of the cell a non-native nucleic acid sequence which is transcribed to produce an mRNA which is complementary to and capable of binding to the mRNA produced by the genetic material of said cell.
    Type: Grant
    Filed: June 21, 1990
    Date of Patent: December 21, 1993
    Assignee: Research Foundation of State University of New York
    Inventors: Masayori Inouye, Takeshi Mizuno, Mei-Yin Chou
  • Patent number: 5190931
    Abstract: Gene expression in a cell can be regulated or inhibited by incorporating into or associating with the genetic material of the cell a non-native nucleic acid sequence which is transcribed to produce an mRNA which is complementary to and capable of binding to the mRNA produced by the genetic material of said cell.
    Type: Grant
    Filed: November 15, 1989
    Date of Patent: March 2, 1993
    Assignee: The Research Foundation of State University of New York
    Inventor: Masayori Inouye
  • Patent number: 4333540
    Abstract: A fixed cutting tool shape for improved rock drilling performance of drag-type rotary bits includes a cemented tungsten carbide cutter body and a plow-shaped cutter element. In a preferred embodiment, the cutter element is a composite compact of polycrystalline diamond on a cemented tungsten carbide substrate, and defines a generally V-shaped cutter to create a plowing action and direct rock ship flow away from the working surface.
    Type: Grant
    Filed: February 11, 1980
    Date of Patent: June 8, 1982
    Assignee: General Electric Company
    Inventors: William H. Daniels, John B. Cheatham, Jr.
  • Patent number: 4300522
    Abstract: A dresser tool comprises two composite compacts positioned to crush and shear the grinding wheel. Preferably one composite compact is arranged such that its working edge contacts the grinding wheel tangentially; and the other compact is placed so that its working edge is normal to the grinding wheel at a rake angle ranging from positive to negative.
    Type: Grant
    Filed: May 16, 1980
    Date of Patent: November 17, 1981
    Assignee: General Electric Company
    Inventors: Robert L. Henry, Frank R. Skinner
  • Patent number: 4239502
    Abstract: A silver-manganese-zirconium brazing alloy with a high percentage of silver at least exceeding 80 percent is used in a process for fabricating strong, high thermal conductivity bonds between diamond or cubic boron nitride (CBN) and a molybdenum or tungsten support member. Typical diamond or CBN-alloy-metal products with the improved alloy bond are semiconductor device heat sinks, grinding wheels and tools.
    Type: Grant
    Filed: November 17, 1978
    Date of Patent: December 16, 1980
    Assignee: General Electric Company
    Inventors: Glen A. Slack, Warren S. Knapp
  • Patent number: 4225322
    Abstract: A component comprised of a composite compact, preferably diamond, and a substrate bonded to the compact. A preferred embodiment of the component is a cutter for a drill bit. The compact is comprised of a layer of bonded diamond or boron nitride particles and a base layer of cemented carbide bonded, preferably under high temperatures and pressures, to the particulate layer. The particulate layer is degradable by exposure to temperatures above a predetermined temperature. The substrate is bonded to the base layer of the compact with a filler metal which, to form a bond, requires the exposure of the surfaces to be bonded to a temperature substantially greater than the degradation temperature of the particulate layer. The component is fabricated by heating the base layer, filler metal and substrate to a temperature in excess of the degradation temperature while maintaining the temperature of the particulate layer below the degradation temperature via a heat sink.
    Type: Grant
    Filed: January 10, 1978
    Date of Patent: September 30, 1980
    Assignee: General Electric Company
    Inventor: Friedel S. Knemeyer
  • Patent number: 4199035
    Abstract: An apparatus for rock cutting and drilling. A preferred embodiment of the apparatus is a drill bit comprised of composite compact cutters removably secured or attached to the drill crown. The cutter is preferably comprised of a stud or pin with an abrasive composite compact bonded at one end of the stud. The securing means for the cutter is comprised of a sleeve and a bushing fixed in the recess of the bit crown. The sleeve has a threaded outer wall for engagement with a threaded inner wall of the bushing. The height of the cutter is adjustable by the provision of metal shims between the bottom of the recess and the base of the stud of the cutter.
    Type: Grant
    Filed: April 24, 1978
    Date of Patent: April 22, 1980
    Assignee: General Electric Company
    Inventor: Donald A. Thompson